CTX310 Receives Two FDA RMAT Designations
In a November 2 disclosure recovered in the 36-hour window, CRISPR Therapeutics said FDA granted Regenerative Medicine Advanced Therapy (RMAT) designations to CTX310 for severe hypertriglyceridemia and elevated LDL-C. The company also reported third-quarter…
